Tariq M, Ayub F, Altaf I, Bashir R, Bin Shabir S, Almas S
Vet Res Forum. 2024; 15(7):351-356.
PMID: 39257459
PMC: 11383201.
DOI: 10.30466/vrf.2024.2004394.3908.
Miyamoto Y
Gels. 2023; 9(4).
PMID: 37102933
PMC: 10137452.
DOI: 10.3390/gels9040321.
Abdoli A, Aalizadeh R, Aminianfar H, Kianmehr Z, Teimoori A, Azimi E
Rev Med Virol. 2021; 32(3):e2305.
PMID: 34699647
PMC: 8646699.
DOI: 10.1002/rmv.2305.
K B M, Nayar S, P V M
Biotechnol J. 2021; 17(1):e2100188.
PMID: 34665927
PMC: 8646257.
DOI: 10.1002/biot.202100188.
Ruseska I, Fresacher K, Petschacher C, Zimmer A
Nanomaterials (Basel). 2021; 11(6).
PMID: 34200384
PMC: 8230241.
DOI: 10.3390/nano11061508.
COVID-19 vaccine platforms: Delivering on a promise?.
Verdecia M, Kokai-Kun J, Kibbey M, Acharya S, Venema J, Atouf F
Hum Vaccin Immunother. 2021; 17(9):2873-2893.
PMID: 34033528
PMC: 8381795.
DOI: 10.1080/21645515.2021.1911204.
Impact of virus genetic variability and host immunity for the success of COVID-19 vaccines.
Dos Santos W
Biomed Pharmacother. 2021; 136:111272.
PMID: 33486212
PMC: 7802525.
DOI: 10.1016/j.biopha.2021.111272.
A brief outlook on the current emerging trends of COVID 19 vaccines.
Smitha T, Thomas A
J Oral Maxillofac Pathol. 2021; 24(2):206-211.
PMID: 33456225
PMC: 7802844.
DOI: 10.4103/jomfp.JOMFP_334_20.
Nanocarrier vaccines for SARS-CoV-2.
Machhi J, Shahjin F, Das S, Patel M, Abdelmoaty M, Cohen J
Adv Drug Deliv Rev. 2021; 171:215-239.
PMID: 33428995
PMC: 7794055.
DOI: 10.1016/j.addr.2021.01.002.
Assessment of inactivation procedures for SARS-CoV-2.
Auerswald H, Yann S, Dul S, In S, Dussart P, Martin N
J Gen Virol. 2021; 102(3).
PMID: 33416462
PMC: 8148305.
DOI: 10.1099/jgv.0.001539.
Impact of Protein Glycosylation on the Design of Viral Vaccines.
Schon K, Lepenies B, Goyette-Desjardins G
Adv Biochem Eng Biotechnol. 2020; 175:319-354.
PMID: 32935143
DOI: 10.1007/10_2020_132.
A Narrative Review of Pediatric Nontraumatic Spinal Cord Dysfunction.
New P
Top Spinal Cord Inj Rehabil. 2019; 25(2):112-120.
PMID: 31068743
PMC: 6496964.
DOI: 10.1310/sci2502-112.
Poliomyelitis era in Trinidad from 1940 to 1972 and beyond: Implications for effective global health governance for its eradication.
Mungrue K, Chattu V
J Family Med Prim Care. 2018; 7(4):664-670.
PMID: 30234035
PMC: 6132009.
DOI: 10.4103/jfmpc.jfmpc_319_17.
Novel vaccines: Technology and development.
Patil S, Shreffler W
J Allergy Clin Immunol. 2018; 143(3):844-851.
PMID: 29970235
PMC: 6311446.
DOI: 10.1016/j.jaci.2018.05.021.
Review of the History of Non-traumatic Spinal Cord Dysfunction.
New P, Biering-Sorensen F
Top Spinal Cord Inj Rehabil. 2018; 23(4):285-298.
PMID: 29339905
PMC: 5667426.
DOI: 10.1310/sci2304-285.
'A matter of commonsense': the Coventry poliomyelitis epidemic 1957 and the British public.
Millward G
Contemp Br Hist. 2017; 31(3):384-406.
PMID: 29118656
PMC: 5652641.
DOI: 10.1080/13619462.2016.1247701.
Let microorganisms do the talking, let us talk more about microorganisms.
Nai C, Magrini B, Offe J
Fungal Biol Biotechnol. 2017; 3:5.
PMID: 28955464
PMC: 5611652.
DOI: 10.1186/s40694-016-0023-9.
Addressing the Challenges and Opportunities of the Polio Endgame: Lessons for the Future.
Patel M, Cochi S
J Infect Dis. 2017; 216(suppl_1):S1-S8.
PMID: 28838196
PMC: 5853839.
DOI: 10.1093/infdis/jix117.
Plant-made polio type 3 stabilized VLPs-a candidate synthetic polio vaccine.
Marsian J, Fox H, Bahar M, Kotecha A, Fry E, Stuart D
Nat Commun. 2017; 8(1):245.
PMID: 28811473
PMC: 5557999.
DOI: 10.1038/s41467-017-00090-w.
Chemical Attenuation in the Development of a Whole-Organism Malaria Vaccine.
Raja A, Stanisic D, Good M
Infect Immun. 2017; 85(7).
PMID: 28438976
PMC: 5478957.
DOI: 10.1128/IAI.00062-17.
